Genelux Common Net Worth

Genelux Common Net Worth Breakdown

  GNLX
The net worth of Genelux Common is the difference between its total assets and liabilities. Genelux Common's net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Genelux Common's assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Genelux Common's net worth can be used as a measure of its financial health and stability which can help investors to decide if Genelux Common is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Genelux Common stock.

Genelux Common Net Worth Analysis

Genelux Common's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Genelux Common's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Genelux Common's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Genelux Common's net worth analysis. One common approach is to calculate Genelux Common's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Genelux Common's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Genelux Common's net worth. This approach calculates the present value of Genelux Common's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Genelux Common's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Genelux Common's net worth. This involves comparing Genelux Common's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Genelux Common's net worth relative to its peers.

Enterprise Value

352.12 Million

To determine if Genelux Common is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Genelux Common's net worth research are outlined below:
Genelux Common is way too risky over 90 days horizon
Genelux Common appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 170 K. Net Loss for the year was (28.3 M) with profit before overhead, payroll, taxes, and interest of 11.07 M.
Genelux Common generates negative cash flow from operations
About 16.0% of the company shares are held by company insiders
Latest headline from finance.yahoo.com: Frazier Life Sciences Appoints John Smither and Jim Williams as Senior Advisors
Genelux Common uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Genelux Common. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Genelux Common's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
13th of February 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View
13th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Genelux Common Target Price Consensus

Genelux target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Genelux Common's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
   5  Strong Buy
Most Genelux analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Genelux stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Genelux Common, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice   Exposure   Valuation

Genelux Common Target Price Projection

Genelux Common's current and average target prices are 2.69 and 34.33, respectively. The current price of Genelux Common is the price at which Genelux Common is currently trading. On the other hand, Genelux Common's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.

Current Price

Genelux Common Market Quote on 2nd of December 2024

Low Price2.64Odds
High Price2.72Odds

2.69

Target Price

Analyst Consensus On Genelux Common Target Price

Low Estimate31.24Odds
High Estimate38.11Odds

34.33

Historical Lowest Forecast  31.24 Target Price  34.33 Highest Forecast  38.11
Note that most analysts generally publish their price targets in research reports on specific companies, along with recommendations for the company's stock.Although price targets are often quoted in the financial news media, there could be a delay between the publication of the latest analyst outlook on Genelux Common and the information provided on this page.

Follow Genelux Common's market capitalization trends

The company currently falls under 'Micro-Cap' category with a current market capitalization of 92.91 M.

Market Cap

359.37 Million

Project Genelux Common's profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(1.01)(1.07)
Return On Capital Employed(1.13)(1.08)
Return On Assets(1.01)(1.07)
Return On Equity(1.45)(1.38)
When accessing Genelux Common's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Genelux Common's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Genelux Common's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Genelux Common's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Genelux Common. Check Genelux Common's Beneish M Score to see the likelihood of Genelux Common's management manipulating its earnings.

Evaluate Genelux Common's management efficiency

Genelux Common has return on total asset (ROA) of (0.4461) % which means that it has lost $0.4461 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8857) %, meaning that it created substantial loss on money invested by shareholders. Genelux Common's management efficiency ratios could be used to measure how well Genelux Common manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.07 in 2024. Return On Capital Employed is likely to rise to -1.08 in 2024. At this time, Genelux Common's Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 25.4 M in 2024, whereas Net Tangible Assets are likely to drop (31.3 M) in 2024.
Last ReportedProjected for Next Year
Book Value Per Share 0.80  0.84 
Tangible Book Value Per Share 0.80  0.84 
Enterprise Value Over EBITDA(12.68)(13.31)
Price Book Value Ratio 17.58  18.45 
Enterprise Value Multiple(12.68)(13.31)
Price Fair Value 17.58  18.45 
Enterprise Value335.4 M352.1 M
The decision-making processes within Genelux Common are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Enterprise Value Revenue
7.6 K
Revenue
K
Quarterly Revenue Growth
(0.95)
Return On Equity
(0.89)
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Genelux Common insiders, such as employees or executives, is commonly permitted as long as it does not rely on Genelux Common's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Genelux Common insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Scigalla Paul over a month ago
Acquisition by Scigalla Paul of 16666 shares of Genelux Common at 6.0 subject to Rule 16b-3
 
Thomas John over two months ago
Acquisition by Thomas John of 2500 shares of Genelux Common at 5.25 subject to Rule 16b-3
 
Yong Yu over two months ago
Disposition of 5200 shares by Yong Yu of Genelux Common at 19.106 subject to Rule 16b-3
 
Joseph Cappello over two months ago
Acquisition by Joseph Cappello of 11557 shares of Genelux Common subject to Rule 16b-3
 
Szalay Aladar over two months ago
Disposition of 33080 shares by Szalay Aladar of Genelux Common at 2.5679 subject to Rule 16b-3
 
Szalay Aladar over two months ago
Disposition of 31777 shares by Szalay Aladar of Genelux Common at 2.7294 subject to Rule 16b-3
 
Szalay Aladar over two months ago
Disposition of 31376 shares by Szalay Aladar of Genelux Common at 2.6207 subject to Rule 16b-3
 
Szalay Aladar over two months ago
Disposition of 20384 shares by Szalay Aladar of Genelux Common at 2.5109 subject to Rule 16b-3
 
Szalay Aladar over two months ago
Disposition of 23383 shares by Szalay Aladar of Genelux Common at 2.7028 subject to Rule 16b-3
 
Szalay Aladar over three months ago
Disposition of 142589 shares by Szalay Aladar of Genelux Common at 2.173 subject to Rule 16b-3
 
Szalay Aladar over three months ago
Disposition of 15918 shares by Szalay Aladar of Genelux Common at 2.0483 subject to Rule 16b-3
 
Szalay Aladar over three months ago
Disposition of 51630 shares by Szalay Aladar of Genelux Common at 2.1085 subject to Rule 16b-3

Genelux Common Corporate Filings

10Q
14th of November 2024
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
ViewVerify
8K
8th of November 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
13A
25th of October 2024
The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934
ViewVerify
13A
22nd of October 2024
An amended filing to the original Schedule 13G
ViewVerify
Genelux Common time-series forecasting models is one of many Genelux Common's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Genelux Common's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Genelux Common Earnings Estimation Breakdown

The calculation of Genelux Common's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Genelux Common is estimated to be -0.22125 with the future projection ranging from a low of -0.23 to a high of -0.2125. Please be aware that this consensus of annual earnings estimates for Genelux Common is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
-0.19
-0.23
Lowest
Expected EPS
-0.22125
-0.21
Highest

Genelux Common Earnings Projection Consensus

Suppose the current estimates of Genelux Common's value are higher than the current market price of the Genelux Common stock. In this case, investors may conclude that Genelux Common is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Genelux Common's stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyLast Reported EPSEstimated EPS for 31st of December 2024Current EPS (TTM)
587.41%
-0.19
-0.22125
-0.94

Genelux Common Earnings per Share Projection vs Actual

Actual Earning per Share of Genelux Common refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Genelux Common predict the company's earnings will be in the future. The higher the earnings per share of Genelux Common, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Genelux Common Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Genelux Common, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Genelux Common should always be considered in relation to other companies to make a more educated investment decision.

Genelux Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Genelux Common's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-11-15
2024-09-30-0.19-0.190.0
2024-08-15
2024-06-30-0.2075-0.22-0.0125
2024-05-09
2024-03-31-0.23-0.29-0.0626 
2024-03-29
2023-12-31-0.19-0.25-0.0631 
2023-11-14
2023-09-30-0.18-0.2-0.0211 
2023-08-14
2023-06-30-0.15-0.23-0.0853 
2023-05-15
2023-03-31-0.16-0.53-0.37231 
2023-03-29
2022-12-310-0.12-0.12
2022-09-19
2022-06-300-0.12-0.12
2022-06-24
2022-03-310-0.16-0.16

Genelux Common Corporate Management

Caroline JewettVP QualityProfile
Ralph BScHead AffairsProfile
Sean JDGeneral SecretaryProfile
Lourie ZakChief OfficerProfile
Joseph CappelloChief OfficerProfile
Yong YuSenior DevelopmentProfile

Additional Tools for Genelux Stock Analysis

When running Genelux Common's price analysis, check to measure Genelux Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genelux Common is operating at the current time. Most of Genelux Common's value examination focuses on studying past and present price action to predict the probability of Genelux Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genelux Common's price. Additionally, you may evaluate how the addition of Genelux Common to your portfolios can decrease your overall portfolio volatility.